Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Amgen’s Izervay NDA Accepted by NMPA for Geographic Atrophy Secondary to Age-Related Macular Degeneration

Fineline Cube May 15, 2026
Company Drug

Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma

Fineline Cube May 15, 2026
Company Drug

Boai NKY’s LYC001 Receives Clinical Approval in China for Advanced Solid Tumors

Fineline Cube Jun 11, 2025

China-based Boai NKY Medical Holdings Ltd (SHE: 300109) announced that its joint venture company, Beijing...

Company Drug

Sino Biopharmaceutical’s TQB2868 Approved for Phase III Trial in Metastatic Pancreatic Cancer

Fineline Cube Jun 11, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received approval from the Center...

Company Drug

Ocumension Therapeutics Gains CDE Approval for Phase III Presbyopia Trial

Fineline Cube Jun 11, 2025

Ocumension Therapeutics (HKG: 1477), a Chinese ophthalmology specialist, announced that the Center for Drug Evaluation...

Company Deals

Jiangxi Rimag Plans Acquisition of Changsha Zhongya Medical for RMB 29.5 Million

Fineline Cube Jun 10, 2025

China-based Jiangxi Rimag Group Co., Ltd (HKG: 2522) announced plans to acquire 100% stake in...

Company Drug

Biogen Launches Qalsody in China for SOD1-ALS Treatment

Fineline Cube Jun 10, 2025

US-based Biogen (NASDAQ: BIIB) officially launched Qalsody (tofersen) in China this week. The drug, the...

Company Deals

Boehringer Ingelheim and Echosens Expand Partnership to Tackle MASH

Fineline Cube Jun 10, 2025

Germany-based Boehringer Ingelheim and France-based Echosens have expanded their partnership to enhance early screening, precise...

Others

China Expands Medical Insurance Coverage in New State Council Guidelines

Fineline Cube Jun 10, 2025

The General Office of the State Council released the “Guidelines on Further Safeguarding and Improving...

Company

WuXi Biologics Commences Construction on Microbial Production Base in Chengdu

Fineline Cube Jun 10, 2025

China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced the official...

Company Drug

Sihuan Pharma’s Xuanyuening Granted New Indication Review in China

Fineline Cube Jun 10, 2025

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration...

Company Drug

Johnson & Johnson Launches Tremfya IV in China for Inflammatory Bowel Diseases

Fineline Cube Jun 10, 2025

US-based Johnson & Johnson (J&J; NYSE: JNJ) announced the commercial launch of Tremfya (guselkumab) intravenous...

Company Deals

Deep Surgery Secures Pre-Series A Funding for Microsurgery Robot Expansion

Fineline Cube Jun 10, 2025

Guangzhou-based microsurgery robot developer Deep Surgery has secured “tens of millions” of renminbi in a...

Company

ImmuneOnco Appoints Zhuli Wu as Chief Medical Officer to Lead Clinical Strategy

Fineline Cube Jun 10, 2025

China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced the appointment of Zhuli Wu as...

Company Drug

Hengrui Pharmaceuticals Launches Aiweida for HER2-Mutated NSCLC in China

Fineline Cube Jun 10, 2025

China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced the first commercial shipment of its...

Company Medical Device

Suzhou Sinus Medtech Wins FDA Breakthrough Designation for oHCM Ablation System

Fineline Cube Jun 10, 2025

Suzhou Sinus Medical Technologies Co., Ltd., a China-based medical device innovator, announced that its in-house...

Company Drug

Novartis’ PSMAddition Trial Yields Positive Results for Pluvicto in mHSPC

Fineline Cube Jun 10, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) announced the interim results from its Phase III PSMAddition...

Company Drug

Innovent Biologics’ Xinbiyue Approved for Macau Market

Fineline Cube Jun 10, 2025

China-based Innovent Biologics Inc. (HKG: 1801) announced that it has received market approval from the...

Company Deals

Innogen Pharma Resubmits Hong Kong IPO Application With Promising Diabetes Drug

Fineline Cube Jun 10, 2025

China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd. has resubmitted its application for a main board...

Company Deals

Harrow Signs Licensing Deal for Formosa’s Byqlovi in US Market

Fineline Cube Jun 10, 2025

US-based ophthalmic pharmaceutical company Harrow (NASDAQ: HROW) announced a licensing agreement with Taiwan-based Formosa Pharmaceuticals...

Company Drug

FDA Approves Merck’s Enflonsia for Infant RSV Protection

Fineline Cube Jun 10, 2025

The US Food and Drug Administration (FDA) granted approval to Merck, Sharp & Dohme’s (MSD;...

Company Drug

Sino Biopharmaceutical Gains CDE Approval for TQC3721 COPD Trial

Fineline Cube Jun 10, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received approval from the Center...

Posts pagination

1 … 147 148 149 … 666

Recent updates

  • Alibaba Health Reports Strong FY2026 Results with 35.2% Profit Growth and Launches Medical LLM “H+”
  • Amgen’s Izervay NDA Accepted by NMPA for Geographic Atrophy Secondary to Age-Related Macular Degeneration
  • China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations
  • Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma
  • AstraZeneca Reports Positive Phase III VOLGA Interim Results for Imfinzi-Based Combinations in Muscle-Invasive Bladder Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Digital

Alibaba Health Reports Strong FY2026 Results with 35.2% Profit Growth and Launches Medical LLM “H+”

Company Drug

Amgen’s Izervay NDA Accepted by NMPA for Geographic Atrophy Secondary to Age-Related Macular Degeneration

Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Company Drug

Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.